cycloaddit
nmethyl
c
diethoxyphosphoryl
nitron
gave
isoxazolidin
substitut
quinazolinon
modifi
isoxazolidin
cycloadduct
screen
antivir
activ
broad
spectrum
dna
rna
virus
sever
isoxazolidin
inhibit
replic
thymidin
kinas
wildtyp
defici
tk
tk
varicellazost
viru
strain
ec
rang
well
human
cytomegaloviru
ec
isoxazolidin
exhibit
moder
cytostat
activ
toward
human
lymphocyt
cell
line
cem
ic
molecul
herp
simplex
virus
vaccinia
viru
vacv
ec
wherea
compound
exhibit
activ
vaccinia
viru
e
sm
cell
cultur
mic
anoth
analogu
ie
substitutedbenzalamino
quinazolinon
found
exhibit
antivir
activ
tobacco
mosaic
viru
tmv
vivo
compound
show
cur
effect
slightli
higher
refer
drug
ningnanmycin
recent
one
synthes
evalu
inhibitori
action
replic
influenza
viru
h
n
well
test
toxic
vitro
cell
line
gener
one
contain
chalcon
skeleton
thiosemicarbazon
hydrazid
show
moder
antivir
activ
h
n
inhibit
rate
respect
compar
refer
drug
zanamivir
addit
compound
possess
nitro
group
report
potent
inhibitor
venezuelan
equin
enceph
viru
veev
ec
cc
quinazolinon
display
high
select
appear
potent
inhibitor
hepat
c
viru
hcv
replic
vitro
moreov
compound
exhibit
higher
potenc
atropisom
ar
pic
vs
improv
select
rang
vs
lipid
kinas
molecul
x
molecul
synthes
synthet
strategi
new
isoxazolidineconjug
quinazolinon
reli
cycloaddit
nmethylc
diethoxyphosphoryl
nitron
select
scheme
molecul
x
isoxazolidin
ring
differ
substitu
addit
bromin
atom
synthes
synthet
strategi
new
isoxazolidineconjug
quinazolinon
reli
cycloaddit
nmethylc
diethoxyphosphoryl
nitron
select
scheme
scheme
retrosynthesi
isoxazolidin
conjug
herpesvirus
envelop
icosahedr
virus
contain
doublestrand
dna
fundament
distinguish
herpesvirus
other
abil
establish
latent
infect
reactiv
host
immun
system
impair
human
cytomegaloviru
hcmv
varicella
zoster
viru
vzv
belong
famili
herpesvirus
caus
infect
usual
acquir
childhood
treatment
viral
infect
caus
herpesvirus
includ
vzv
hcmv
sever
drug
acyclovir
eg
zovirax
valacyclovir
eg
valtrex
famciclovir
eg
famvir
brivudin
eg
zostex
helpin
ganciclovir
eg
cymeven
use
despit
wide
rang
avail
drug
effect
treatment
viral
infect
still
limit
mainli
due
specif
viral
infect
abil
virus
mutat
associ
acquisit
drug
resist
therefor
new
compound
potenti
biolog
activ
sought
time
quinazolinon
deriv
extens
studi
wide
rang
biolog
activ
includ
antivir
anticanc
antifung
antibacteri
antitubercular
antiinflammatori
anticonvuls
hypolipidem
analges
immunotrop
properti
antivir
activ
compound
contain
framework
discov
recent
year
figur
exampl
benzoic
acid
report
possess
distinct
antivir
activ
antivir
activ
compound
contain
framework
discov
recent
year
figur
exampl
benzoic
acid
report
possess
distinct
antivir
activ
herp
simplex
virus
vaccinia
viru
vacv
wherea
compound
exhibit
activ
vaccinia
viru
cell
cultur
mic
anoth
analogu
ie
substitutedbenzalamino
quinazolinon
found
exhibit
antivir
activ
tobacco
mosaic
viru
tmv
vivo
compound
show
cur
effect
slightli
higher
refer
drug
ningnanmycin
recent
one
synthes
evalu
inhibitori
action
replic
influenza
viru
well
test
toxic
vitro
cell
line
gener
one
contain
chalcon
skeleton
thiosemicarbazon
hydrazid
show
moder
antivir
activ
inhibit
rate
respect
compar
refer
drug
zanamivir
addit
compound
possess
nitro
group
report
potent
inhibitor
venezuelan
equin
enceph
viru
veev
quinazolinon
display
high
select
appear
potent
inhibitor
hepat
c
viru
hcv
replic
vitro
moreov
compound
exhibit
higher
potenc
atropisom
ar
vs
improv
select
rang
vs
lipid
kinas
recent
succeed
synthesi
seri
quinazolinon
substitut
diethoxyphosphoryl
isoxazolidin
moieti
sever
synthes
analogu
exhibit
moder
activ
varicella
zoster
viru
vzv
human
cytomegaloviru
hcmv
basi
observ
continu
search
new
biolog
activ
compound
novel
seri
quinazolinon
deriv
gener
formula
recent
succeed
synthesi
seri
quinazolinon
substitut
diethoxyphosphoryl
isoxazolidin
moieti
sever
synthes
analogu
exhibit
moder
activ
varicella
zoster
viru
vzv
human
cytomegaloviru
hcmv
basi
observ
continu
search
new
biolog
activ
compound
novel
seri
quinazolinon
deriv
gener
formula
isoxazolidin
ring
differ
substitu
addit
bromin
atom
cycloaddit
nitron
respect
carri
toluen
afford
mixtur
diastereoisomer
isoxazolidin
scheme
tabl
ratio
transci
diastereoisom
determin
basi
pnmr
spectra
crude
product
confirm
analysi
hnmr
spectra
data
case
good
transci
diastereoselect
observ
rang
transisom
predomin
mixtur
isoxazolidin
cycloadduct
separ
chromatograph
silica
gel
isol
pure
isom
success
accomplish
major
isom
r
h
r
r
r
r
scheme
retrosynthesi
isoxazolidin
conjug
respect
synthes
start
commerci
avail
isato
acid
anhydrid
first
react
bromin
transform
acid
amid
accord
procedur
literatur
reaction
acid
amid
chlorid
follow
cycliz
dehydrohalogen
led
format
use
key
intermedi
prepar
deriv
via
alkyl
respect
benzyl
bromid
well
methyl
ethyl
iodid
scheme
molecul
x
isoxazolidin
ring
differ
substitu
addit
bromin
atom
synthes
synthet
strategi
new
isoxazolidineconjug
quinazolinon
reli
cycloaddit
nmethylc
diethoxyphosphoryl
nitron
select
scheme
scheme
retrosynthesi
isoxazolidin
conjug
respect
synthes
start
commerci
avail
isato
acid
anhydrid
first
react
bromin
transform
acid
amid
accord
procedur
literatur
reaction
acid
amid
chlorid
follow
cycliz
dehydrohalogen
led
format
use
key
intermedi
prepar
deriv
via
alkyl
respect
benzyl
bromid
well
methyl
ethyl
iodid
scheme
scheme
synthesi
reaction
condit
chlorid
b
naohetoh
c
rbr
koh
mei
eti
koh
cycloaddit
nitron
respect
carri
toluen
afford
mixtur
diastereoisomer
isoxazolidin
scheme
tabl
ratio
transci
diastereoisom
determin
basi
pnmr
spectra
crude
product
confirm
analysi
hnmr
spectra
data
case
good
transci
diastereoselect
observ
rang
transisom
predomin
mixtur
isoxazolidin
cycloadduct
separ
chromatograph
silica
gel
isol
pure
isom
success
accomplish
major
isom
r
h
r
r
r
r
scheme
synthesi
reaction
condit
chlorid
c
b
naohetoh
c
rbr
koh
c
mei
eti
koh
ch
cn
c
cycloaddit
nitron
respect
carri
c
toluen
afford
mixtur
diastereoisomer
isoxazolidin
scheme
tabl
ratio
transci
diastereoisom
determin
basi
pnmr
spectra
crude
product
confirm
analysi
hnmr
spectra
data
case
good
transci
diastereoselect
observ
rang
transisom
predomin
mixtur
isoxazolidin
cycloadduct
separ
chromatograph
silica
gel
isol
pure
isom
success
accomplish
major
isom
r
h
r
c
h
ch
r
c
h
ch
r
c
h
ch
r
c
h
ch
r
h
ch
r
h
ch
r
ch
r
ch
ch
well
minor
isom
r
h
stereochemistri
cycloaddit
nitron
deriv
recent
describ
rel
configur
transand
cisisoxazolidin
cycloadduct
establish
base
conform
analysi
sinc
introduct
bromin
atom
framework
influenc
stereochem
outcom
reaction
nitron
tran
ci
configur
major
minor
isom
assign
take
advantag
previou
observ
pure
isom
well
diastereoisomer
mixtur
isoxazolidin
test
inhibitori
activ
wide
varieti
dna
rna
virus
follow
cellbas
assay
use
human
embryon
lung
hel
cell
herp
simplex
ko
strain
herp
simplex
g
strain
thymidin
kinas
defici
acyclovir
resist
herp
simplex
tk
ko
acv
r
vaccinia
viru
vesicular
stomat
viru
cytomegaloviru
davi
strain
varicellazost
viru
tk
vzv
tk
vzv
strain
b
hela
cell
cultur
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
c
vero
cell
cultur
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
yellow
fever
viru
crfk
cell
cultur
felin
corona
viru
fipv
felin
herp
viru
fhv
e
mdck
cell
cultur
influenza
viru
subtyp
influenza
b
viru
ganciclovir
cidofovir
acyclovir
brivudin
zalcitabin
zanamivir
alovudin
amantadin
rimantadin
ribavirin
dextran
sulfat
molecular
weight
mycophenol
acid
hippeastrum
hybrid
agglutinin
hha
urtica
dioica
agglutinin
stereochemistri
cycloaddit
nitron
deriv
recent
describ
rel
configur
transand
cisisoxazolidin
cycloadduct
establish
base
conform
analysi
sinc
introduct
bromin
atom
framework
influenc
stereochem
outcom
reaction
nitron
tran
ci
configur
major
minor
isom
assign
take
advantag
previou
observ
pure
isom
well
diastereoisomer
mixtur
isoxazolidin
test
inhibitori
activ
wide
varieti
dna
rna
virus
follow
cellbas
assay
use
human
embryon
lung
hel
cell
herp
simplex
ko
strain
herp
simplex
g
strain
thymidin
kinas
defici
acyclovir
resist
herp
simplex
tk
ko
acv
r
vaccinia
viru
vesicular
stomat
viru
cytomegaloviru
davi
strain
varicellazost
viru
tk
vzv
tk
vzv
strain
b
hela
cell
cultur
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
c
vero
cell
cultur
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
yellow
fever
viru
crfk
cell
cultur
felin
corona
viru
fipv
felin
herp
viru
fhv
e
mdck
cell
cultur
influenza
viru
subtyp
influenza
b
viru
ganciclovir
cidofovir
acyclovir
brivudin
zalcitabin
zanamivir
alovudin
amantadin
rimantadin
ribavirin
dextran
sulfat
molecular
weight
mycophenol
acid
hippeastrum
hybrid
agglutinin
hha
urtica
dioica
agglutinin
uda
use
refer
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
viru
plaqu
format
vzv
reduc
virusinduc
cytopathogen
virus
almost
synthes
isoxazolidin
inhibit
replic
tk
tk
vzv
strain
ec
rang
tabl
time
inact
toward
test
virus
except
hcmv
gener
inhibitori
activ
test
compound
toward
tk
vzv
strain
better
refer
drug
acyclovir
brivudin
ec
ec
respect
requir
activ
viral
enzym
hand
activ
compound
tk
vzv
oka
strain
five
ninefold
lower
refer
drug
acyclovir
brivudin
respect
exhibit
signific
activ
toward
tk
tk
vzv
stain
compound
exhibit
lowest
cytotox
cc
worth
mention
incorpor
bromin
atom
quinazolinon
skeleton
result
signific
increas
potenc
isoxazolidineconjug
vzv
fivefold
higher
compar
previous
describ
analog
conjug
unsubstitut
quinazolin
skeleton
synthes
isoxazolidin
phosphon
also
show
mark
activ
human
cytomegaloviru
hcmv
tabl
among
potent
one
activ
test
compound
davi
strain
compar
ec
ganciclovir
ec
use
refer
drug
still
lower
refer
drug
cidofovir
ec
cytostat
inhibitori
concentr
ic
caus
decreas
cell
prolifer
determin
murin
leukemia
human
lymphocyt
cem
human
cervix
carcinoma
hela
immort
human
dermal
microvacsular
endotheli
cell
almost
compound
show
inhibitori
activ
prolifer
tumour
cell
line
tabl
appear
cytostat
toward
human
tlymphocyt
cem
cell
line
inhibitori
effect
rang
thu
isoxazolidin
ic
ic
ic
ic
ic
ic
ic
exhibit
activ
toward
cem
line
higher
ic
tabl
inhibitori
effect
test
compound
prolifer
murin
leukemia
human
tlymphocyt
cem
human
cervix
carcinoma
hela
immort
human
dermal
microvascular
endotheli
cell
structureact
relationship
studi
indic
isoxazolidin
deriv
possess
hydrogen
methyl
ethyl
quinazolinon
ring
activ
test
virus
inhibit
prolifer
test
cell
line
compound
substitut
benzyl
moieti
found
effect
vzv
hcmv
abl
inhibit
tumour
cell
line
growth
moreov
isoxazolidin
phosphon
substitu
quinazolinon
core
show
highest
antivir
activ
ec
valu
rang
hand
compound
possess
substitu
posit
show
inhibitori
effect
prolifer
murin
leukemia
human
tlymphocyt
cem
cell
line
wherea
isoxazolidin
substitu
posit
quinazolinon
moieti
appear
activ
toward
human
cervix
carcinoma
hela
cell
line
howev
inhibitori
concentr
much
lower
refer
drug
follow
adsorb
use
column
chromatographi
merck
silica
gel
mesh
analyt
tlc
merck
merck
kgaa
darmstadt
germani
tlc
plastic
sheet
silica
gel
f
nmethylc
diethoxyphosphoryl
nitron
acid
amid
obtain
accord
procedur
literatur
solut
amid
g
mmol
ml
chlorid
ml
mmol
ad
min
c
argon
atmospher
mixtur
stir
room
temperatur
h
dilut
water
precipit
appear
collect
wash
water
ml
mixtur
benzamid
g
mmol
sodium
hydroxid
ml
ethanol
ml
stir
reflux
min
solut
allow
cool
min
acidifi
acet
acid
ml
precipit
collect
wash
water
ml
crude
one
purifi
crystal
methanol
solut
g
mmol
acetonitril
ml
potassium
hydroxid
g
mmol
ad
min
respect
benzyl
bromid
mmol
ad
reaction
mixtur
stir
reflux
h
solvent
remov
residu
redissolv
methylen
chlorid
ml
extract
water
ml
organ
phase
dri
mgso
concentr
crude
product
purifi
silica
gel
column
methylen
chlorid
hexan
vv
mixtur
follow
crystal
chloroformpetroleum
ether
ethyl
acet
give
pure
quinazolinon
nch
anal
calcd
c
solut
g
mmol
acetonitril
ml
potassium
hydroxid
g
mmol
ad
min
iodomethan
ml
mmol
iodoethan
ml
mmol
ad
reaction
mixtur
stir
c
h
solvent
remov
residu
redissolv
methylen
chlorid
ml
extract
water
ml
organ
layer
dri
mgso
concentr
crude
product
purifi
silica
gel
column
methylen
chlorid
hexan
mixtur
vv
mixtur
follow
crystal
chloroform
petroleum
ether
hz
dd
j
hz
j
hz
chch
dd
j
hz
j
hz
chch
dd
j
hz
j
hz
chch
ch
solut
nitron
g
mmol
respect
one
mmol
toluen
ml
stir
c
disappear
tlc
start
nitron
solvent
evapor
vacuo
crude
product
subject
chromatographi
silica
gel
column
chloroform
methanol
vv
mixtur
ch
n
j
hz
ch
ch
op
j
hz
ch
ch
op
viral
cytopath
plaqu
format
vzv
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopath
viral
plaqu
format
cytotox
test
compound
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
cell
morpholog
altern
cytostat
activ
test
compound
measur
base
inhibit
cell
growth
hel
cell
seed
rate
cellswel
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
three
day
incub
c
cell
number
determin
coulter
counter
cytostat
concentr
calcul
cc
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
murin
leukemia
human
tlymphocyt
cem
human
cervix
carcinoma
hela
immort
human
dermal
microvascular
endotheli
cell
suspend
cellsml
cultur
medium
cell
suspens
ad
appropri
dilut
test
compound
microtit
plate
incub
c
two
three
cem
four
hela
day
cell
number
determin
use
coulter
counter
ic
defin
compound
concentr
requir
inhibit
cell
prolifer
seri
isoxazolidineconjug
quinazolinon
obtain
nmethyl
c
diethoxyphosphoryl
nitron
select
transisoxazolidin
cycloadduct
isoxazolidin
respect
mixtur
isoxazolidin
evalu
antivir
activ
toward
varieti
dna
rna
virus
almost
compound
activ
vzv
among
potent
ec
time
exhibit
lower
cytotox
toward
uninfect
cell
line
cc
furthermor
isoxazolidin
phosphon
show
highest
activ
hcmv
ec
hand
sever
compound
exhibit
moder
cytostat
effect
toward
cem
cell
line
ic
howev
slightli
higher
use
refer
drug
prove
instal
function
benzyl
group
quinazolinon
moieti
essenti
inhibitori
properti
toward
vzv
hcmv
time
notic
incorpor
bromin
atom
quinazolinon
skeleton
result
signific
increas
potenc
isoxazolidineconjug
toward
vzv
fivefold
higher
hcmv
threefold
higher
compar
previous
describ
analog
conjug
lack
bromin
substitu
quinazolinon
moieti
moreov
inhibitori
properti
newli
synthes
compound
toward
test
cell
line
also
slightli
higher
previous
describ
analogu
author
contribut
research
group
medic
univers
lodz
dgp
mgd
conceiv
research
project
particip
step
research
interpret
result
discuss
experiment
data
prepar
manuscript
research
group
ku
leuven
ga
ds
rs
conduct
biolog
assay
provid
experiment
procedur
result
author
read
comment
approv
manuscript
